Serena Williams’ recent use of GLP-1 weight-loss medication has drawn fresh attention because of her status as one of the most recognizable athletes in the world and her return to tennis after retiring. Williams previously partnered with Ro, a company linked to her husband, Alexis Ohanian, and publicly said she used Zepbound after struggling to lose weight following the births of her two daughters. Her openness has made her the most prominent athlete to acknowledge using a GLP-1 drug for weight loss, especially as she has also appeared in paid promotions connected to the treatment.
The discussion has expanded beyond Williams herself and into a larger debate about whether GLP-1 medications should be treated as performance-enhancing drugs in sports. Anti-doping authorities, including those in tennis, began paying closer attention to these drugs in 2024 after their rapid rise in popularity. For now, GLP-1 medications are not banned, and the World Anti-Doping Agency does not currently classify them as performance-enhancing substances. That position could still change, but it is not clear that it will.
In tennis, anti-doping matters are handled by the International Tennis Integrity Agency, with WADA overseeing compliance. The current debate centers on whether GLP-1s offer any real athletic advantage. Supporters of a ban could argue that the drugs promote weight loss and may therefore affect body composition in ways that matter in sport. Others point out that studies have found GLP-1 users can lose muscle as well as fat, which may actually hurt athletic performance rather than improve it.
The article argues that the issue is not simple and that sports regulations often reflect broader political and cultural forces, not just clear performance effects. Some substances and treatments are banned in competition even when they do not directly improve performance, while others remain controversial because of how they intersect with identity, medicine, and fairness debates. The same pattern may shape the future of GLP-1 rules if anti-doping bodies decide to revisit the issue.
The broader concern is not only whether GLP-1s should be banned in sports, but also how athletes’ endorsements can shape public attitudes. When elite athletes promote these drugs as a path to weight loss, it can make them seem like a normal or “healthy” option for people who do not medically need them. The article suggests that this is especially troubling given the medical nature of the drugs and the fact that they are not intended for casual cosmetic use.
Ultimately, Serena Williams’ use of GLP-1 medication has become a focal point in a much bigger conversation about athletic integrity, body image, medical treatment, and the line between personal health choices and sports regulation.
